Stage III bladder transitional cell carcinoma represents an advanced phase of cancer that requires thorough understanding and coordinated treatment approaches to achieve the best possible outcomes and maintain quality of life.

Understanding Treatment Goals and Options for Advanced Bladder Cancer

When bladder transitional cell carcinoma reaches stage III, the cancer has grown beyond the bladder’s inner layers and spread into surrounding tissues. At this point, treatment becomes more complex and typically involves multiple approaches working together. The main goals of treatment are to remove or destroy cancer cells, prevent the disease from spreading further, manage symptoms, and help patients maintain the best possible quality of life during and after therapy.^[3]

Treatment decisions for stage III bladder cancer depend on several important factors. The exact location and extent of the cancer, the patient’s overall health condition, and individual preferences all play crucial roles in determining the best treatment path. In females, the cancer may have reached the uterus or vagina, while in males it might involve the prostate or seminal vesicles. However, at stage III, the cancer has not yet spread to distant organs or lymph nodes far from the bladder.^[3]

Medical teams typically include multiple specialists working together. A urologist (a doctor specializing in urinary system disorders), a medical oncologist (a cancer specialist who manages drug treatments), and a radiation oncologist (a specialist in radiation therapy) may all contribute to developing and implementing the treatment plan. This team approach ensures that all available treatment options are considered and that care is coordinated effectively.^[8]

Both standard treatments that have been proven effective through years of medical practice and newer experimental therapies being tested in clinical trials are available for stage III bladder cancer. Standard treatments are recommended by medical societies and have established track records, while clinical trial treatments offer access to cutting-edge therapies that may provide additional benefits. Understanding both options helps patients and their families make informed decisions about their care.

Standard Treatment Approaches for Stage III Bladder Cancer

The cornerstone of treatment for stage III bladder cancer is typically radical cystectomy, which is surgery to remove the entire bladder. This operation also removes surrounding tissues and organs that may be affected by cancer. In men, this includes the prostate and seminal vesicles. In women, the uterus, fallopian tubes, ovaries, anterior vaginal wall, and urethra are typically removed. The procedure usually also includes removal of nearby lymph nodes to check for cancer spread and reduce the risk of recurrence.^[8]

After the bladder is removed, surgeons must create a new way for the body to store and pass urine. This is called urinary diversion. Modern techniques often involve creating an artificial bladder called a neobladder or continent reservoir. These reconstructions can preserve normal voiding function in many cases, significantly improving quality of life compared to older methods. The specific type of urinary diversion depends on the extent of surgery needed and the patient’s overall health.^[8]

Chemotherapy is almost always offered for stage II and III bladder cancer. It is most commonly given before surgery, an approach called neoadjuvant chemotherapy. This timing allows the drugs to shrink the tumor before removal, potentially making surgery more successful and reducing the risk of cancer returning. Chemotherapy can also be given after surgery if it wasn’t used beforehand, to eliminate any remaining cancer cells that might not be visible.^[17]

The standard chemotherapy approach uses combinations of drugs that include cisplatin. Cisplatin is a platinum-based chemotherapy agent that interferes with cancer cell DNA, preventing the cells from dividing and growing. It is typically combined with other chemotherapy drugs to increase effectiveness. Common combinations include gemcitabine with cisplatin, or regimens like MVAC (methotrexate, vinblastine, doxorubicin, and cisplatin). These drugs are given through a vein over several treatment cycles, usually spanning several months.^[17]

For patients who cannot undergo surgery or who wish to preserve their bladder, a combined approach called trimodality therapy or bladder-preserving treatment may be possible. This approach combines three treatments: surgery to remove visible tumors through the urethra (called transurethral resection of bladder tumor or TURBT), chemotherapy, and radiation therapy. The chemotherapy in this setting often includes cisplatin or a combination of 5-fluorouracil and mitomycin, which work together with radiation to destroy cancer cells.^[8]

Radiation therapy uses high-energy beams to kill cancer cells. External radiation therapy, delivered from a machine outside the body, may be given alone if surgery cannot be performed, or as part of the bladder-preserving approach after TURBT. When combined with chemotherapy, radiation becomes more effective because the chemotherapy drugs make cancer cells more vulnerable to radiation damage. This process is called radiosensitization.^[17]

The duration of treatment varies depending on the specific approach. Chemotherapy before surgery typically involves three to four cycles given over several months. Radiation therapy, when used, is usually delivered five days a week for several weeks. The entire treatment process from diagnosis through completion of all therapies and initial recovery can take six months to a year or longer.

Side effects from these treatments can be significant and vary depending on which therapies are used. Chemotherapy commonly causes fatigue, nausea, vomiting, hair loss, increased risk of infection due to low white blood cell counts, and damage to kidneys or nerves. Cisplatin specifically can affect hearing and kidney function, requiring careful monitoring. Radiation therapy to the pelvis can cause bladder irritation, diarrhea, skin reactions in the treatment area, and long-term effects on bowel and sexual function. Surgery carries risks including bleeding, infection, blood clots, and complications specific to urinary diversion such as leakage or obstruction.^[3]

Emerging Treatments Being Studied in Clinical Trials

Clinical trials are research studies that test new treatments or new combinations of existing treatments. For stage III bladder cancer, several innovative approaches are currently being investigated. These trials aim to improve survival rates, reduce side effects, and offer options for patients whose cancer does not respond to standard treatments.

Immunotherapy represents one of the most promising areas of clinical research for bladder cancer. These treatments work by helping the patient’s own immune system recognize and attack cancer cells. Immune checkpoint inhibitors are immunotherapy drugs that block proteins that prevent immune cells from attacking cancer. When these proteins are blocked, the immune system can mount a stronger response against the tumor.^[17]

Several immune checkpoint inhibitors are being studied or used for advanced bladder cancer. These include drugs that target a protein called PD-1 or its partner PD-L1. When cancer cells display PD-L1 on their surface, they can essentially hide from immune attack. By blocking this interaction, checkpoint inhibitors allow immune cells called T-cells to recognize and destroy cancer cells. Some of these drugs may be offered for stage 3 bladder cancer that continues growing during or after chemotherapy with cisplatin, or that comes back within 12 months of finishing chemotherapy.^[17]

These immunotherapy drugs are given through an intravenous infusion, typically every few weeks. Unlike chemotherapy, which directly kills rapidly dividing cells, immunotherapy may take longer to show effects because it works by activating the immune system. Side effects are also different from chemotherapy and relate to immune system overactivation. These can include fatigue, skin rashes, diarrhea, and inflammation of organs like the lungs, liver, or intestines. While usually manageable, these immune-related side effects require careful monitoring and sometimes treatment with immune-suppressing medications.

Targeted therapy is another innovative approach being used for advanced bladder cancer. Unlike chemotherapy, which affects all rapidly dividing cells, targeted therapies attack specific molecules or pathways that cancer cells use to grow and survive. One example is erdafitinib, a drug that targets mutations in genes called FGFR2 or FGFR3. These genes normally help control cell growth, but when mutated, they can drive cancer development.^[17]

Erdafitinib is a type of drug called an FGFR inhibitor. It works by blocking the abnormal signals from mutated FGFR proteins that tell cancer cells to grow and divide. This drug can be used for locally advanced bladder cancer that has specific FGFR mutations and has not responded to chemotherapy. Before using erdafitinib, doctors test tumor samples to confirm the presence of these specific mutations. The drug is taken by mouth as a pill, making it more convenient than intravenous treatments. Side effects can include dry mouth, dry eyes, changes in phosphate levels in the blood, nail problems, and diarrhea.^[17]

Clinical trials are also exploring newer forms of immunotherapy beyond checkpoint inhibitors. Some studies are testing vaccines designed to train the immune system to recognize bladder cancer cells. Others are investigating adoptive cell therapy, where a patient’s own immune cells are removed, modified in the laboratory to better fight cancer, and then returned to the patient’s body. These approaches are in earlier phases of testing but show promise.

Combination approaches are another major focus of clinical trials. Researchers are studying whether combining immunotherapy with chemotherapy, or combining different types of immunotherapy together, produces better results than single treatments. Some trials are investigating whether giving immunotherapy before surgery (neoadjuvant immunotherapy) can shrink tumors and prevent recurrence more effectively than chemotherapy alone.

Clinical trials are conducted in phases. Phase I trials test a new treatment in a small group of people to evaluate safety, determine safe dosage ranges, and identify side effects. Phase II trials involve larger groups and aim to determine whether the treatment is effective against the cancer and to further evaluate safety. Phase III trials compare the new treatment with standard treatments in large groups of patients to confirm effectiveness, monitor side effects, and collect information that allows the treatment to be used safely. Many clinical trials for stage III bladder cancer are in Phase II or Phase III.

Clinical trials for bladder cancer are conducted at major cancer centers in the United States, Europe, and other regions around the world. Some trials specifically recruit patients from certain geographic areas, while others may be open to patients from multiple countries. Eligibility often depends on specific characteristics of the cancer, such as whether it has certain genetic mutations, how it has responded to previous treatments, and the patient’s overall health status.

Most common treatment methods

• Surgery
  • Radical cystectomy involves complete removal of the bladder along with surrounding tissues and organs
  • In men, this includes removal of the prostate and seminal vesicles
  • In women, the uterus, fallopian tubes, ovaries, anterior vaginal wall, and urethra are typically removed
  • Pelvic lymph node dissection is performed to remove nearby lymph nodes
  • Urinary diversion surgery creates a new way to store and pass urine, often using a neobladder or continent reservoir
  • Transurethral resection of bladder tumor (TURBT) removes visible tumors through the urethra and may be part of bladder-preserving approaches
• Chemotherapy
  • Cisplatin-based combination chemotherapy is the standard approach, typically given before surgery
  • Common regimens include gemcitabine with cisplatin, or MVAC (methotrexate, vinblastine, doxorubicin, and cisplatin)
  • Drugs are given intravenously over several treatment cycles spanning months
  • Can also be combined with radiation therapy as part of bladder-preserving treatment
  • 5-fluorouracil and mitomycin may be used in combination with radiation for bladder preservation
• Radiation Therapy
  • External beam radiation therapy uses high-energy beams to kill cancer cells
  • Often combined with chemotherapy (chemoradiation) for better effectiveness
  • May be used as part of bladder-preserving treatment after TURBT
  • Can be given alone if surgery is not possible
  • Typically delivered five days per week for several weeks
• Immunotherapy
  • Immune checkpoint inhibitors block proteins that prevent immune cells from attacking cancer
  • Target PD-1 or PD-L1 proteins to help the immune system recognize cancer cells
  • May be offered for cancer that grows during or after cisplatin chemotherapy
  • Given through intravenous infusion every few weeks
  • Used for cancer that has high risk of coming back or cannot be treated with surgery or chemotherapy
• Targeted Therapy
  • Erdafitinib targets mutations in FGFR2 or FGFR3 genes
  • Works by blocking abnormal growth signals from mutated FGFR proteins
  • Used for locally advanced cancer with specific FGFR mutations that did not respond to chemotherapy
  • Taken orally as a pill
  • Requires genetic testing of tumor to confirm presence of FGFR mutations
• Bladder-Preserving (Trimodality) Therapy
  • Combines TURBT surgery, chemotherapy, and radiation therapy
  • Aims to preserve bladder function while treating cancer
  • May be option for patients who cannot undergo or do not want radical surgery
  • Requires close surveillance with frequent cystoscopy follow-ups
  • Salvage cystectomy may be needed if cancer returns locally